loader2
Partner With Us NRI

Company details

908.20
921.00
733.95
966.90
6M Return 1.84%
1Y Return 15.86%
Mkt Cap.(Cr) 218,459.45
Volume 33,475
Div Yield 1.09%
OI
-
OI Chg %
-
Volume 33,475

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Our Research View

Trading recommendation

Data not found

Investment recommendation

Call Date

30 Jul 2022

Entry Price

944.00

Target Price

1,125.00

Duration

12-18 Month

Rapid Results

Q1FY23 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Announced Q1FY23 Result :

  • Q1 Gross Sales at Rs. 106,440 million up 10.1% YoY
  • Q1 Net Profit at Rs. 20,609 million up 42.7% YoY
  • Gross sales at Rs. 106,440 million, growth of 10.1% over Q1 last year. Excluding Covid products sales for Q1 last year, overall sales are up by about 14%
  • India formulation sales at Rs. 33,871 million, up 13% on like-to-like basis, excluding Covid products sales of Q1 last year. On reported basis, the growth is 2.4% over Q1 last year
  • US formulation sales at US$ 420 million, growth of 10.7% over Q1 last year
  • Emerging Markets formulation sales at US$ 245 million, up by 12.6% over Q1 last year
  • Rest of World formulation sales at US$ 190 million, up by 2.6% over same quarter last year
  • R&D investments at Rs. 4,608 million compared to Rs. 5,926 million for Q1FY22
  • EBITDA at Rs. 28,844 million (including other operating revenues), with EBITDA margin at 26.8%
  • Net profit for the quarter was at Rs. 20,609 million, up by 42.7% YoY. Excluding the exceptional items of Q1 last year, adjusted net profit was up by 4.1%.
  • Production Linked Incentive (PLI) scheme – will help in further improving technology capabilities, capacity utilization and competitiveness.

Dilip Shanghvi, Managing Director of the Company said, “For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our specialty business and all-round growth across markets. Specialty business has grown by 29% driven by Ilumya, Cequa, Odomzo and Winlevi. Our India business continues to grow faster than market, leading to increase in market share. We have been able to report healthy margins despite rising costs. We continue to focus on expanding our global specialty business, growing all our businesses and improving our market share.”

Result PDF

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 24,587.95 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 2,384.58 23,141.09
LAST 3M 49,521.50 -18,551.54
LAST 6M 129,719.68 -157,153.27
LAST 12M 215,295.98 -222,611.80

Information

  • About Company
  • Company Info
  • Listing Info
28.6
54.48%
200.1022
7.43%
8.66%

No Data Found

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524715
NSE Code : SUNPHARMA
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE044A01036

ICICIdirect Sun Pharmaceuticals Industries Ltd FAQ

You can buy Sun Pharmaceuticals Industries Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Sun Pharmaceuticals Industries Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Aug 08, 2022 04:01 PM the closing price of Sun Pharmaceuticals Industries Ltd was ₹ 910.50.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Aug 08, 2022 04:01 PM, the market cap of Sun Pharmaceuticals Industries Ltd stood at ₹ 218,459.45.
The latest PE ratio of Sun Pharmaceuticals Industries Ltd as of Aug 08, 2022 04:01 PM is 28.6
The latest PB ratio of Sun Pharmaceuticals Industries Ltd as of Aug 08, 2022 04:01 PM is 0.22
The 52-week high of Sun Pharmaceuticals Industries Ltd is ₹ 966.90 while the 52-week low is ₹ 733.95 .
According to analyst recommendations, Sun Pharmaceuticals Industries Ltd has a “Buy” rating for the long term.

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE